Open access

Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer
Carmine Carbone, Geny Piro, Antonio Agostini, Pietro Delfino, Francesco De Sanctis, Vincenzo Nasca, Francesco Spallotta, Claudio Sette, Maurizio Martini, Stefano Ugel, Vincenzo Corbo, Paola Cappello, Emilio Bria, Aldo Scarpa, Giampaolo Tortora

Journal for ImmunoTherapy of Cancer Sep 2021, 9 (9) e002876; DOI: 10.1136/jitc-2021-002876
Correction: THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy
Journal for ImmunoTherapy of Cancer Sep 2021, 9 (9) 1; DOI: 10.1136/jitc-2021-002443orr1
Correction: Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids
Journal for ImmunoTherapy of Cancer Sep 2021, 9 (9) 1; DOI: 10.1136/jitc-2021-003000corr1
BHLHE22 drives the immunosuppressive bone tumor microenvironment and associated bone metastasis in prostate cancer
Chi Yin, Min Wang, Yingzhao Wang, Qijun Lin, Kaiyuan Lin, Hong Du, Chuandong Lang, Yuhu Dai, Xinsheng Peng

Journal for ImmunoTherapy of Cancer Mar 2023, 11 (3) e005532; DOI: 10.1136/jitc-2022-005532
Invasive margin tissue-resident macrophages of high CD163 expression impede responses to T cell-based immunotherapy
Marit J van Elsas, Camilla Labrie, Anders Etzerodt, Pornpimol Charoentong, Jordi J C van Stigt Thans, Thorbald Van Hall, Sjoerd H van der Burg

Journal for ImmunoTherapy of Cancer Mar 2023, 11 (3) e006433; DOI: 10.1136/jitc-2022-006433
Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors
Konstantinos Lontos, Yiyang Wang, Supriya K Joshi, Andrew T Frisch, McLane J Watson, Alok Kumar, Ashley V Menk, Yupeng Wang, Rachel Cumberland, Jason Lohmueller, Esteban Carrizosa, Benjamin Boyerinas, Greg M Delgoffe

Journal for ImmunoTherapy of Cancer Mar 2023, 11 (3) e006522; DOI: 10.1136/jitc-2022-006522
First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)
Karen A Autio, Celestia S Higano, Luke Nordquist, Leonard J Appleman, Tian Zhang, Xin-Hua Zhu, Hani Babiker, Nicholas J Vogelzang, Sandip M Prasad, Michael T Schweizer, Ravi A Madan, Stephane Billotte, Nora Cavazos, Orlaith Bogg, Ray Li, Kam Chan, Helen Cho, Megan Kaneda, I-Ming Wang, Jenny Zheng, Szu-Yu Tang, Robert Hollingsworth, Kenneth A Kern, Daniel P Petrylak

Journal for ImmunoTherapy of Cancer Mar 2023, 11 (3) e005702; DOI: 10.1136/jitc-2022-005702
LAL deficiency induced myeloid-derived suppressor cells as targets and biomarkers for lung cancer
Ting Zhao, Sheng Liu, Nasser H Hanna, Shadia Jalal, Xinchun Ding, Jun Wan, Cong Yan, Hong Du

Journal for ImmunoTherapy of Cancer Mar 2023, 11 (3) e006272; DOI: 10.1136/jitc-2022-006272
Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy
Rasmus Erik Johansson Mortensen, Morten Orebo Holmström, Thomas Landkildehus Lisle, Jane P Hasselby, Gro L Willemoe, Özcan Met, Inge Marie Svane, Julia Johansen, Dorte L Nielsen, Inna M Chen, Mads Hald Andersen

Journal for ImmunoTherapy of Cancer Mar 2023, 11 (3) e006432; DOI: 10.1136/jitc-2022-006432
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F McDermott, Mehmet A Bilen, Mark Stein, Jeffrey A Sosman, Robert Alter, Elizabeth R Plimack, Moshe C Ornstein, Michael Hurwitz, David J Peace, Sabina Signoretti, Thomas Denize, Alessia Cimadamore, Catherine J Wu, David Braun, David Einstein, Paul J Catalano, Hans Hammers

Journal for ImmunoTherapy of Cancer Mar 2023, 11 (3) e004780; DOI: 10.1136/jitc-2022-004780

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages